Published: 2 September 2021
Publications
Recent approvals: new active ingredients or new indications
Published: 2 September 2021
Prescriber Update 42(3): 36
September 2021
For the period 16 April 2021 to 15 July 2021.
Recent approvals of medicines with new active ingredients
| Trade name (active ingredient) | Dose form and strength(s) | Therapeutic area |
|---|---|---|
| Beovu (brolizumab) | Solution for injection 120 mg/mL vial 120 mg/mL pre-filled syringe |
Neovascular age-related macular degeneration |
| COVID-19 Vaccine Janssen* (Ad26.COV2.s) | Suspension for injection 5x1010 virus particles/0.5 mL |
Immunisation to prevent COVID-19 in adults aged 18 years and older |
Approved medicines with new indications
| Trade Name (active ingredient) | Dose form and strength(s) | New therapeutic area(s) |
|---|---|---|
| Biktarvy (bictegravir; emtricitabine; tenofovir alafenamide) | Film coated tablet 50 mg/200 mg/25 mg |
HIV-1 infection in paediatric patients weighing at least 25 kg |
| Cabometyx (cabozantinib) | Film coated tablet 20 mg 40 mg 60 mg |
Hepatocellular carcinoma |
| Comirnaty (COVID-19 mRNA vaccine)* | Concentrate for injection 0.5 mg/mL |
Immunisation to prevent COVID-19 in adolescents aged 12 to 15 years old |
| Dysport (botulinum toxin type A) | Powder for injection 300 U 500 U |
Focal spasticity of upper limbs in children aged 2 years and older |
| Zavicefta (ceftazidime; avibactam) | Powder for infusion 2000 mg/500 mg |
Infections in paediatric (aged 3 months and older) patients |
* Comirnaty has provisional approval.
See the Medsafe website for:
